Lowers Compugen (NASDAQ:CGEN) to Hold cut shares of Compugen (NASDAQ:CGENFree Report) from a buy rating to a hold rating in a research report report published on Tuesday.

Separately, Truist Financial reduced their target price on shares of Compugen from $5.00 to $4.00 and set a buy rating on the stock in a research note on Tuesday, May 21st.

Get Our Latest Analysis on CGEN

Compugen Price Performance

Shares of Compugen stock opened at $2.05 on Tuesday. The firm has a 50 day simple moving average of $2.12 and a 200 day simple moving average of $2.04. Compugen has a fifty-two week low of $0.53 and a fifty-two week high of $3.03. The firm has a market cap of $177.58 million, a P/E ratio of -10.79 and a beta of 2.71.

Compugen (NASDAQ:CGENGet Free Report) last released its earnings results on Monday, May 20th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. The firm had revenue of $2.56 million for the quarter, compared to the consensus estimate of $2.79 million. On average, sell-side analysts expect that Compugen will post 0.05 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Heron Bay Capital Management bought a new stake in Compugen in the first quarter valued at about $32,000. Tocqueville Asset Management L.P. bought a new stake in shares of Compugen in the 3rd quarter valued at about $71,000. Finally, Silverarc Capital Management LLC raised its position in shares of Compugen by 6.1% in the 3rd quarter. Silverarc Capital Management LLC now owns 350,188 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 20,000 shares during the period. 12.22% of the stock is currently owned by institutional investors.

About Compugen

(Get Free Report)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.

Featured Stories

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with's FREE daily email newsletter.